Side-by-side financials for AVTX and ABBV. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AVTX | ABBV |
|---|---|---|
| Market cap | - | $402.35 B |
| US-listed rank | - | #31 |
| Revenue (latest FY) | $59.00K | $61.16B |
| Net income (latest FY) | -$78.26M | $4.23B |
| Net margin | -132642.4% | 6.9% |
| P/E (trailing FY) | - | 95.2 |
| SEC filings | 997 | 1,008 |
In their latest fiscal years, Avalo Therapeutics, Inc. reported $59.00K in revenue while AbbVie Inc. reported $61.16B.
Full pages: Avalo Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.